Proteus syndrome is an extremely rare condition that causes asymmetric, disproportionate overgrowth of bones, skin, and other tissues. It affects fewer than a few hundred people worldwide. Children with Proteus syndrome typically appear normal at birth, but overgrowth becomes visible during childhood and progressively worsens, sometimes dramatically altering the shape and size of affected body parts while leaving the rest of the body unchanged.
What Causes Proteus Syndrome
Proteus syndrome is caused by a single-letter misspelling in the DNA of a gene called AKT1, which helps regulate cell growth. This mutation doesn’t come from either parent. Instead, it occurs spontaneously in one cell during early embryonic development. Every cell that descends from that original mutated cell carries the error, while the rest of the body’s cells remain normal. This creates a patchwork pattern called somatic mosaicism, where some tissues overgrow and others don’t.
The timing of the mutation matters enormously. If it happens very early in development, more of the body’s cells will carry it, and the condition tends to be more severe. If it happens later, fewer cells are affected and the overgrowth may be more limited. The mutation essentially jams the accelerator on cell growth, but only in the tissues descended from that one original cell. Because it arises randomly during development rather than being inherited, Proteus syndrome doesn’t run in families.
How Overgrowth Develops Over Time
Most children with Proteus syndrome show few or no signs at birth, though rare cases have been identified with limb differences from the start. Overgrowth typically becomes noticeable during childhood and continues to progress, sometimes rapidly. The hallmark features are macrodactyly (enlarged fingers or toes), limb length discrepancy, and asymmetric overgrowth of limbs, skull, or vertebrae. It’s not unusual for a child to develop a leg-length difference of more than 10 centimeters (about 4 inches) before age 10.
The overgrowth doesn’t just make bones bigger. It distorts their architecture, particularly around joints. Irregular, disorganized bone formation can invade joint spaces, leading to stiffness and immobility. Scoliosis is common and tends to appear around the same age as typical adolescent scoliosis. The spine curvature can progress quickly and may require early intervention.
Skin Changes and Distinctive Findings
One of the most characteristic signs is a skin feature called a cerebriform connective tissue nevus, a thickened, deeply grooved patch of skin that resembles the surface of the brain. It most commonly appears on the soles of the feet and can cause significant problems: pain, itching, infection, bleeding, odor, and difficulty walking. This finding is so specific to Proteus syndrome that it is the sole feature in Category A of the diagnostic criteria, meaning its presence alone (alongside the general criteria) can confirm the diagnosis.
Other skin findings include linear epidermal nevi, which are raised, streak-like patches on the skin. Some patients also develop abnormal fat distribution, with areas of either excess or missing fatty tissue, and vascular malformations affecting capillaries, veins, or lymphatic vessels.
How Proteus Syndrome Is Diagnosed
Diagnosis relies on clinical criteria developed by the National Institutes of Health. Three general features must all be present: the overgrowth follows a mosaic (patchy) distribution, no one else in the family has similar features, and the overgrowth has visibly progressed over time or spread to new areas.
Beyond those three requirements, doctors look for specific findings organized into three tiers:
- Category A: A cerebriform connective tissue nevus. This alone, with the general criteria, is enough for diagnosis.
- Category B: Includes linear epidermal nevi, asymmetric overgrowth of at least two structures (limbs, skull, vertebrae, or internal organs), or specific benign tumors appearing in the first decade of life. Two Category B features are needed if no Category A feature is present.
- Category C: Includes abnormal fat tissue distribution, vascular malformations, lung cysts, or a characteristic facial appearance with a long face, low nasal bridge, and wide nostrils. Three Category C features are required if nothing from Categories A or B is met.
Genetic testing for the AKT1 mutation can support the diagnosis, but because the mutation only exists in affected tissues, standard blood tests may miss it. A biopsy from an overgrown area is sometimes needed to detect it.
Serious Medical Complications
The most dangerous complication of Proteus syndrome is blood clotting. People with the condition face an elevated risk of deep vein thrombosis, particularly in affected limbs. If a clot travels to the lungs, it causes a pulmonary embolism, which can be fatal. In one study of 57 people with Proteus syndrome, six of the ten who had died had deep vein thrombosis and pulmonary embolism as their confirmed cause of death. Among the 47 living patients in that study, six had experienced non-fatal clotting events, all occurring after surgery and in an overgrown limb.
Clotting risk is compounded by the fact that many patients show abnormalities in blood clotting factors. Over half of patients tested in one analysis had abnormal results on coagulation panels, including conditions like Factor V Leiden or protein C and S deficiencies. Surgery on affected limbs carries particular risk and requires careful clot-prevention planning.
Proteus syndrome also increases the risk of certain benign tumors, including ovarian cystadenomas and parotid gland tumors. Some patients develop lung cysts that can rupture. Cancer risk, while less common than thromboembolism, has been documented as a cause of death.
Life Expectancy
A survival analysis of Proteus syndrome patients found that roughly 75% survive into adulthood, with a 25% probability of death by age 22. Ten of eleven deaths in the study occurred before age 22, with only a single death after that age. This suggests that the highest-risk period is childhood and adolescence, when overgrowth is most active and surgical interventions are most frequent. For those who survive past early adulthood, the outlook improves considerably. The leading causes of premature death are pulmonary embolism, followed by complications from tumors.
Treatment and Management
There is no cure for Proteus syndrome. Treatment focuses on managing overgrowth and preventing complications. Orthopedic care makes up a large part of management. For limb-length differences, surgeons can use growth plate procedures to slow down the faster-growing leg, sometimes timed by comparing the child’s bone growth to parental hand size as a reference for expected adult proportions. Spinal bracing may begin when a curve is as small as 10 degrees, and expandable growing rods can be placed early to guide the spine before a full fusion is feasible.
In some cases, amputation of a severely overgrown, non-functional limb and fitting with a prosthesis can significantly improve quality of life and mobility. Joint replacement is sometimes an alternative. Soft-tissue releases performed early can help prevent painful contractures and preserve joint function.
Researchers have explored a targeted drug called miransertib, an AKT inhibitor designed to block the exact pathway that drives overgrowth in Proteus syndrome. A clinical trial (called MOSAIC) tested this drug in patients aged two and older, but it was terminated early for business reasons rather than safety concerns. Whether AKT inhibitors will eventually reach patients remains uncertain, but the approach of targeting the specific molecular defect represents the most promising direction for treatment.
How It Differs From Similar Conditions
Proteus syndrome is frequently confused with other overgrowth disorders, particularly CLOVES syndrome (congenital lipomatous overgrowth with vascular malformations and epidermal nevi). The key differences lie in timing and pattern. In CLOVES syndrome, the overgrowth is present at birth, tends to be “ballooning” in character, grows proportionally with the child, and usually affects both feet. In Proteus syndrome, overgrowth is typically absent at birth, distorts and reshapes the affected structures disproportionately, and is strikingly one-sided. The two conditions also have different genetic causes: CLOVES involves the PIK3CA gene, while Proteus involves AKT1, though both genes sit on the same cell growth signaling pathway.